Off-market insider buying at Antibe Therapeutics (ATE)

Off-market insider buying at Antibe Therapeutics (T:ATE)

John Lawrence Wallace, a Senior Officer, Director and 10% Holder, acquired 49,729 Common Shares on a direct ownership basis and 10,967 Common Shares on a control or direction basis for registered holder AltaPharm International Inc. at a price of $5.150 through a private transaction on March 3rd, 2021. This represents a $312,584 investment into the company's shares and an account share holdings change of 20.0%.

Daniel Marcel Legault, CEO, Director and 10% Holder, acquired 29,742 Common Shares on a direct ownership basis and 7,546 Common Shares on a control or direction basis for registered holder Schmed Enterprises Inc. This represents a $192,033 investment into the company's shares and an account share holdings change of 18.9%.

Two other insiders also reported buying shares in smaller amounts.

Antibe Therapeutics is in the Biotechnology & Medical Research Sub Industry Group under the Healthcare Sector.

Antibe Therapeutics Inc. is a commercial-stage pharmaceutical company. The Company is focused on pain, inflammation and regenerative medicine. The Company's segments include Antibe Therapeutics, and Citagenix, which is a marketer and distributor of regenerative medicines serving the dental and orthopedic market places. The Company's drug design methodologies involve chemically linking a base drug to its hydrogen sulfide-releasing molecule. Its lead compound, ATB-346, combines hydrogen sulfide with naproxen, which is a non-steroidal anti-inflammatory drug (NSAID). The Company's other products include ATB-352, which is indicated for the treatment of severe acute pain, and ATB-340 is a Gastrointestinal (GI)-safe derivative of aspirin. The Company also offers regenerative medical devices, which include PentOS (CGX-283), CGX-227, CGX-443 and URIST (CGX-276), all of which target bone regeneration, and are indicated for oral and maxillofacial surgery.